Every month, somewhere in the world, a research group publishes something encouraging about male hormonal contraception. Every couple of years, a headline announces that the male pill is “almost here.” And then, somehow, it is never actually here.
This is not because the scientists are incompetent. It is because the biology is genuinely harder than it looks — and then, piled on top of the genuine biological challenges, are several layers of pharmaceutical economics and institutional priorities that would make even the most patient researcher want to take up organic farming.
Let’s start with the biology, because it is legitimately interesting.
The Fundamental Arithmetic Problem
The female reproductive system, from a contraception engineer’s perspective, is relatively manageable. A woman produces one egg per month during her reproductive years. That egg is released during a narrow ovulation window. Block that one event — suppress ovulation, prevent implantation, or block fertilization — and you have prevented pregnancy.
Women produce on the order of 400 eggs over a reproductive lifetime.
Men, meanwhile, produce approximately 1,000 sperm per second. That is not a typo. One thousand per second. The human testicle operates as a continuous sperm factory running 24 hours a day, producing roughly 1,500 sperm per heartbeat. A single ejaculate typically contains 40 to 300 million sperm, depending on the man and circumstances. Over a lifetime, a man may produce approximately 500 billion sperm.
To effectively contracept a man, you need to suppress this industrial-scale production down to levels that cannot achieve fertilization. The current scientific target is below 1 million sperm per milliliter of ejaculate (the threshold below which clinical trials have documented negligible pregnancy rates). Normal sperm concentration is defined as greater than 15 million per milliliter, per World Health Organization criteria.
Getting from 50+ million/mL to under 1 million/mL is not a minor reduction. It is a ~98% suppression of output. In a biological system that is actively trying to produce sperm continuously.
Where Testosterone Comes In
Here is the elegant part of the story. The hypothalamic-pituitary-testicular (HPT) axis — the hormonal control system for sperm production — has a built-in off switch, and testosterone is the key.
The system works like this in a normal eugonadal man:
- The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses.
- GnRH stimulates the pituitary to release two gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
- LH binds to Leydig cells in the testes, stimulating them to produce testosterone. FSH binds to Sertoli cells, which — in the presence of high local testosterone concentrations — support spermatogenesis.
- Testosterone enters the bloodstream and exerts negative feedback at the hypothalamus and pituitary, suppressing GnRH, LH, and FSH.
This negative feedback loop is the mechanism. When you administer exogenous testosterone — from outside the body — the hypothalamus and pituitary perceive high testosterone and shut down GnRH, LH, and FSH production. LH suppression means the Leydig cells stop making intratesticular testosterone. FSH suppression means the Sertoli cells lose the hormonal support they need for spermatogenesis. The sperm factory slows down, and eventually — over 8–16 weeks in most men — shuts down to very low levels.
The testicular machinery is intact. The feedback signal has simply been redirected. When exogenous testosterone is removed, the natural pulse generator restarts, gonadotropins recover, intratesticular testosterone returns, and spermatogenesis resumes. Every properly conducted trial of male hormonal contraception has confirmed this reversibility — all men who participated recovered normal spermatogenesis after stopping treatment.
So the concept works. Testosterone suppresses sperm production via HPT axis feedback, does not cause hypogonadism (because you are providing the testosterone externally), and is fully reversible.
The catch — and there is always a catch — is that it does not work reliably in all men. And at the doses needed to suppress sperm production to contraceptive levels, you are delivering supraphysiologic testosterone, which carries its own problems.
The Dose Dilemma
To suppress LH and FSH enough to shut down spermatogenesis, you need sustained high levels of circulating testosterone. The WHO trials in the 1990s used 200 mg of testosterone enanthate by intramuscular injection every week. The normal male physiologic range is 300–1,000 ng/dL. Those weekly injections pushed levels considerably higher, particularly in the days following injection.
This creates a pharmacological tension: the contraceptive mechanism requires enough testosterone to suppress the HPT axis reliably, but high testosterone exposure over time creates potential risks — polycythemia (elevated red blood cell count), changes in lipid profiles, potential effects on prostate and liver, and the mood and behavioral changes that can accompany supraphysiologic androgen levels.
Progestins address part of this problem. When you add a progestogen to the regimen, you get two mechanisms suppressing the HPT axis — the androgen feedback loop and the progestogen’s own suppressive effect on gonadotropins. This means you can use lower testosterone doses while achieving the same or better spermatogenic suppression. Most of the more recent male contraceptive trials have used testosterone plus a progestogen rather than testosterone alone, and the results have been more consistent.
The 30% Problem
The second major biological challenge is ethnic and individual variability in response.
In the landmark WHO trials, approximately 70% of men achieved azoospermia (zero sperm) or severe oligozoospermia (below the contraceptive threshold) on weekly testosterone enanthate injections. The remaining roughly 30% did not reach adequate suppression, despite receiving the same regimen.
This ethnic disparity was notable and reproducible: Asian men achieved higher rates of azoospermia than non-Asian men on the same regimen. The WHO 1990 trial found that 71% of men in the azoospermia group were from non-Asian centers, but Asian centers showed higher success rates. The mechanism underlying this variability is not well understood — differences in androgen receptor polymorphisms have been studied and do not fully explain it — but it has been a persistent obstacle to designing a contraceptive that works reliably across all user populations.
A contraceptive that works for 70% of users is not a contraceptive. It is a contraceptive with a 30% failure rate before you even account for user error and compliance. That is worse than condoms.
Later formulations — particularly the combination of testosterone undecanoate with norethisterone enanthate tested in the WHO/CONRAD trial (2016) — achieved over 95% suppression to below 1 million/mL. That is a meaningful improvement. It also came with side effects significant enough that the trial’s independent safety committee recommended early termination.
Why This Matters More Than It Seems
The biological challenges of male contraception are not insurmountable. The suppression works in most men. It is reversible. At carefully calibrated doses with appropriate progestogen co-administration, it approaches the efficacy of female hormonal methods. The science exists.
What does not exist is a formulation that is simultaneously effective in all men, practically deliverable (not weekly injections), acceptable in its side effect profile, and commercially attractive enough to sustain the investment required to bring it to market.
That gap between scientific feasibility and commercial product is what Series 8 is really about. The biology is one chapter. The pharmaceutical economics, the regulatory pathway, the side effect double standard, and the question of who society expects to bear the burden of contraception are separate — and in some ways more complicated — chapters.
The next several posts will go through them in detail: the WHO trials that proved it worked, the candidate molecules that came tantalizingly close, the gel study that showed a path forward, and the systemic reasons that path remains largely untraveled.
Next up: Post 2 — The WHO Testosterone Trials of the 1990s: the landmark studies that proved male hormonal contraception works in principle, and what their limitations revealed about the real problem.
